全文获取类型
收费全文 | 19146篇 |
免费 | 1729篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 696篇 |
妇产科学 | 477篇 |
基础医学 | 2445篇 |
口腔科学 | 324篇 |
临床医学 | 2045篇 |
内科学 | 3731篇 |
皮肤病学 | 210篇 |
神经病学 | 2020篇 |
特种医学 | 640篇 |
外科学 | 2454篇 |
综合类 | 401篇 |
一般理论 | 27篇 |
预防医学 | 2147篇 |
眼科学 | 507篇 |
药学 | 1381篇 |
中国医学 | 16篇 |
肿瘤学 | 1220篇 |
出版年
2023年 | 226篇 |
2022年 | 375篇 |
2021年 | 731篇 |
2020年 | 418篇 |
2019年 | 578篇 |
2018年 | 606篇 |
2017年 | 437篇 |
2016年 | 467篇 |
2015年 | 527篇 |
2014年 | 646篇 |
2013年 | 843篇 |
2012年 | 1264篇 |
2011年 | 1172篇 |
2010年 | 626篇 |
2009年 | 510篇 |
2008年 | 937篇 |
2007年 | 992篇 |
2006年 | 921篇 |
2005年 | 855篇 |
2004年 | 856篇 |
2003年 | 699篇 |
2002年 | 699篇 |
2001年 | 386篇 |
2000年 | 360篇 |
1999年 | 343篇 |
1998年 | 185篇 |
1997年 | 153篇 |
1996年 | 154篇 |
1995年 | 110篇 |
1994年 | 127篇 |
1993年 | 135篇 |
1992年 | 295篇 |
1991年 | 265篇 |
1990年 | 216篇 |
1989年 | 205篇 |
1988年 | 201篇 |
1987年 | 201篇 |
1986年 | 180篇 |
1985年 | 170篇 |
1984年 | 126篇 |
1983年 | 103篇 |
1982年 | 86篇 |
1981年 | 84篇 |
1980年 | 100篇 |
1979年 | 85篇 |
1978年 | 83篇 |
1976年 | 95篇 |
1974年 | 82篇 |
1973年 | 99篇 |
1972年 | 93篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
2.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
3.
4.
5.
Hannah Lilly Mackenzie Bitzel Tatiana Pejnovic Joanna Schnell 《Physical Therapy Reviews》2019,24(5):195-207
AbstractBackground: Cerebral palsy (CP) is a common childhood disability. However, these individuals are now living longer lives, participating in adult roles, and seeking healthcare services. The transition from pediatric to adult healthcare for adolescents with CP is a challenging yet significant time. Adolescents experience several barriers during transition.Objectives: To utilize the environmental and personal dimensions of the ICF model in order to explore barriers when transitioning to adulthood as well as discuss characteristics and physical therapy implications needed to succeed within transition.Methods: Electronic searching of PubMed, CINAHL, ERIC, Scopus, ProQuest, and the Cochrane Library databases was concluded on January 9, 2019 for studies including transition between pediatric and adult healthcare in individuals diagnosed with CP. Two independent reviewers agreed upon inclusion, eligibility, and quality assessment of each study using the Mixed-Methods Appraisal Tool (MMAT).Results: Seven studies were included in the systematic review. Results for each study were separated based on the personal and environmental contextual factors of the ICF model and solutions to the barriers were then discussed.Conclusions: Research has provided proposed solutions to select barriers, however, other barriers have yet to be addressed. More research is needed to address these barriers and provide a model program that can be implemented within the healthcare systems to promote a successful transition for adolescents with CP from pediatric to adult services. 相似文献
6.
7.
8.
9.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
10.